Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US

BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine in some countries) were approved in the US to improve walking in patients with multiple sclerosis, as demonstrated by improvement in walking speed. Postmarketing safety experie...

Descripción completa

Detalles Bibliográficos
Autores principales: Jara, Michele, Barker, Graham, Henney, Herbert R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647381/
https://www.ncbi.nlm.nih.gov/pubmed/23662056
http://dx.doi.org/10.2147/NDT.S41596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647381/
https://www.ncbi.nlm.nih.gov/pubmed/23662056
http://dx.doi.org/10.2147/NDT.S41596

Ejemplares similares